Appendix cancer laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Anmol Pitliya moved page Appendix cancer laboratory tests to Appendix cancer laboratory findings without leaving a redirect) |
(No difference)
| |
Revision as of 16:01, 18 February 2019
|
Appendix cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Appendix cancer laboratory findings On the Web |
|
American Roentgen Ray Society Images of Appendix cancer laboratory findings |
|
Risk calculators and risk factors for Appendix cancer laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
There are no diagnostic laboratory findings associated with appendix cancer in general. Laboratory findings consistent with the diagnosis of carcinoid tumors include , Chromogranin A (CgA), 5-HIAA (5-hydroxyindoleacetic acid) as well as Ki67.[1] [2][3]Some patients with colonic type adenocarcinoma may have elevated concentration of CEA and CA 19-9.[4]
Laboratory Findings
- There are no diagnostic laboratory findings associated with appendix cancer in general.
- Some patients with colonic type adenocarcinoma may have elevated concentration of CEA and CA 19-9.[4][5]
- Laboratory findings consistent with the diagnosis of carcinoid tumor include:
- Chromogranin A (CgA)
- Marker of tumor balk, independent of symptoms
- Specificity: 98.4%, sensitivity: 62.9% [1]
- More sensitive and less specific than urinary 5-HIAA
- 5-HIAA (5-hydroxyindoleacetic acid)
- Ki67
References
- ↑ 1.0 1.1 Gut P, Czarnywojtek A, Fischbach J, Bączyk M, Ziemnicka K, Wrotkowska E et al. (2016) Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch Med Sci 12 (1):1-9. DOI:10.5114/aoms.2016.57577 PMID: 26925113
- ↑ 2.0 2.1 Oberg K (2003) Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 3 (6):863-77. DOI:10.1586/14737140.3.6.863 PMID: 14686708
- ↑ 3.0 3.1 3.2 Maroun J, Kocha W, Kvols L, Bjarnason G, Chen E, Germond C et al. (2006) Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol 13 (2):67-76. PMID: 17576444
- ↑ 4.0 4.1 Carmignani CP, Hampton R, Sugarbaker CE, Chang D, Sugarbaker PH (2004) Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol 87 (4):162-6. DOI:10.1002/jso.20107 PMID: 15334630
- ↑ Oberg K, Janson ET, Eriksson B (1999) Tumour markers in neuroendocrine tumours. Ital J Gastroenterol Hepatol 31 Suppl 2 ():S160-2. PMID: 10604122
- ↑ Eriksson B, Oberg K, Stridsberg M (2000) Tumor markers in neuroendocrine tumors. Digestion 62 Suppl 1 ():33-8. DOI:10.1159/000051853 PMID: 10940685